SLXN fundamentals

An in-depth look to Silexion Therapeutics Corp operating, investing, and financing activities

SLXN free cash flow for Q1 25 is -2.46 M USD. For 2024, SLXN free cash flow was -8.42 M USD and operating cash flow was -8.4 M USD.

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

Cash from operating activities

Cash from investing activities

Cash from financing activities

Currency: USD